JP2016506912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506912A5 JP2016506912A5 JP2015553074A JP2015553074A JP2016506912A5 JP 2016506912 A5 JP2016506912 A5 JP 2016506912A5 JP 2015553074 A JP2015553074 A JP 2015553074A JP 2015553074 A JP2015553074 A JP 2015553074A JP 2016506912 A5 JP2016506912 A5 JP 2016506912A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pharmaceutical composition
- fgfr3
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 7
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 7
- 101000917148 Homo sapiens Fibroblast growth factor receptor 3 Proteins 0.000 claims 5
- 210000000988 bone and bone Anatomy 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102000055709 human FGFR3 Human genes 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 206010008723 Chondrodystrophy Diseases 0.000 claims 3
- 206010058314 Dysplasia Diseases 0.000 claims 3
- 208000008919 achondroplasia Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 108091008794 FGF receptors Proteins 0.000 claims 1
- 206010053759 Growth retardation Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 201000010814 Synostosis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 231100000001 growth retardation Toxicity 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2013/001480 | 2013-01-16 | ||
| PCT/IB2013/001480 WO2014111744A1 (en) | 2013-01-16 | 2013-01-16 | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| PCT/EP2014/050800 WO2014111467A1 (en) | 2013-01-16 | 2014-01-16 | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019021752A Division JP6995069B2 (ja) | 2013-01-16 | 2019-02-08 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506912A JP2016506912A (ja) | 2016-03-07 |
| JP2016506912A5 true JP2016506912A5 (enExample) | 2017-02-16 |
Family
ID=48289519
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553175A Withdrawn JP2016506914A (ja) | 2013-01-16 | 2013-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
| JP2015553074A Withdrawn JP2016506912A (ja) | 2013-01-16 | 2014-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
| JP2019021752A Expired - Fee Related JP6995069B2 (ja) | 2013-01-16 | 2019-02-08 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553175A Withdrawn JP2016506914A (ja) | 2013-01-16 | 2013-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019021752A Expired - Fee Related JP6995069B2 (ja) | 2013-01-16 | 2019-02-08 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20150344855A1 (enExample) |
| EP (2) | EP3736285A1 (enExample) |
| JP (3) | JP2016506914A (enExample) |
| KR (3) | KR20160002681A (enExample) |
| CN (1) | CN105121464B (enExample) |
| AU (2) | AU2013373679A1 (enExample) |
| CA (2) | CA2898415A1 (enExample) |
| DK (1) | DK2945967T3 (enExample) |
| EA (2) | EA201591324A1 (enExample) |
| ES (1) | ES2796743T3 (enExample) |
| HU (1) | HUE049556T2 (enExample) |
| IL (2) | IL239810A0 (enExample) |
| MX (2) | MX372787B (enExample) |
| PE (1) | PE20151664A1 (enExample) |
| PL (1) | PL2945967T3 (enExample) |
| PT (1) | PT2945967T (enExample) |
| SG (2) | SG11201505488XA (enExample) |
| SI (1) | SI2945967T1 (enExample) |
| WO (2) | WO2014111744A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014111744A1 (en) | 2013-01-16 | 2014-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| JP6948945B2 (ja) | 2015-01-07 | 2021-10-13 | ファイザー・インク | 骨格成長障害を治療するための可溶性ｆｇｆｒ３デコイ |
| WO2017188696A1 (ko) * | 2016-04-25 | 2017-11-02 | 장부다 | Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체 |
| CN109715658B (zh) * | 2016-07-07 | 2023-09-12 | 辉瑞大药厂 | 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途 |
| KR20200103621A (ko) * | 2017-09-20 | 2020-09-02 | 화이자 인코포레이티드 | 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩타이드를 사용하는 비정상적 내장 지방 침착의 치료 |
| CN108410803B (zh) * | 2018-03-28 | 2019-02-05 | 湖南源品细胞生物科技有限公司 | 一种诱导脂肪干细胞成软骨分化的培养方法和培养液 |
| CN110272900B (zh) * | 2019-04-19 | 2024-03-26 | 中国人民解放军陆军军医大学 | 用于制备骨骼发育异常猪模型的sgRNA及其应用 |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| JP2022184798A (ja) | 2021-06-01 | 2022-12-13 | ファイザー・インク | ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| IL122473A (en) | 1995-06-12 | 2003-11-23 | Yeda Res & Dev | Fgfr3 as a marker for mesenchymal skeletal progenitor cells |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| EP2119793A1 (en) | 2000-06-28 | 2009-11-18 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| AU2002235202A1 (en) * | 2000-12-18 | 2002-07-01 | Gene Logic, Inc. | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| JP4252746B2 (ja) * | 2001-10-05 | 2009-04-08 | 一和 中尾 | 軟骨無形成症治療剤 |
| JP2003104908A (ja) * | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| US7332299B2 (en) | 2003-02-20 | 2008-02-19 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
| IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| ES2374822T3 (es) | 2004-02-24 | 2012-02-22 | Allergan, Inc. | Ensayo de selección de toxinas botul�?nicas. |
| US7678890B2 (en) * | 2005-07-22 | 2010-03-16 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| WO2008038287A2 (en) | 2006-09-28 | 2008-04-03 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
| CL2007003411A1 (es) | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
| WO2008133873A2 (en) * | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| EP2313435A4 (en) | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
| JP5787757B2 (ja) | 2008-08-04 | 2015-09-30 | ファイブ プライム セラピューティックス インコーポレイテッド | Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質 |
| TWI381848B (zh) | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| HUE061117T2 (hu) | 2009-03-25 | 2023-05-28 | Genentech Inc | Anti-FGFR3 antitestek és eljárások alkalmazásukra |
| CN101585866B (zh) * | 2009-07-02 | 2011-10-05 | 中国人民解放军第三军医大学野战外科研究所 | 调节fgfr3活性的多肽及其筛选方法和应用 |
| US8445445B2 (en) | 2009-09-15 | 2013-05-21 | Five Prime Therapeutics, Inc. | Method of promoting hair growth using FGFR4 extracellular domains |
| AU2010319327B2 (en) | 2009-11-13 | 2015-08-13 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| US8685931B2 (en) | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
| IN2012DN05017A (enExample) | 2010-01-14 | 2015-10-02 | Univ Yale | |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| CA2823066A1 (en) * | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| WO2013063155A2 (en) | 2011-10-24 | 2013-05-02 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| CA2880013C (en) | 2012-07-24 | 2022-11-29 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| CA2878183A1 (en) | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| WO2014071419A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| WO2014111744A1 (en) | 2013-01-16 | 2014-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| MX375032B (es) | 2014-01-24 | 2025-03-06 | Ngm Biopharmaceuticals Inc | Proteínas de unión y métodos para utilizarlas. |
| JP6948945B2 (ja) | 2015-01-07 | 2021-10-13 | ファイザー・インク | 骨格成長障害を治療するための可溶性ｆｇｆｒ３デコイ |
| CN109715658B (zh) | 2016-07-07 | 2023-09-12 | 辉瑞大药厂 | 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途 |
| KR20200103621A (ko) | 2017-09-20 | 2020-09-02 | 화이자 인코포레이티드 | 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩타이드를 사용하는 비정상적 내장 지방 침착의 치료 |
-
2013
- 2013-01-16 WO PCT/IB2013/001480 patent/WO2014111744A1/en not_active Ceased
- 2013-01-16 SG SG11201505488XA patent/SG11201505488XA/en unknown
- 2013-01-16 JP JP2015553175A patent/JP2016506914A/ja not_active Withdrawn
- 2013-01-16 AU AU2013373679A patent/AU2013373679A1/en not_active Abandoned
- 2013-01-16 CA CA2898415A patent/CA2898415A1/en not_active Abandoned
- 2013-01-16 US US14/759,490 patent/US20150344855A1/en not_active Abandoned
- 2013-01-16 EA EA201591324A patent/EA201591324A1/ru unknown
- 2013-01-16 KR KR1020157022203A patent/KR20160002681A/ko not_active Withdrawn
-
2014
- 2014-01-16 AU AU2014206844A patent/AU2014206844A1/en not_active Abandoned
- 2014-01-16 PT PT147022065T patent/PT2945967T/pt unknown
- 2014-01-16 WO PCT/EP2014/050800 patent/WO2014111467A1/en not_active Ceased
- 2014-01-16 JP JP2015553074A patent/JP2016506912A/ja not_active Withdrawn
- 2014-01-16 EP EP20167861.2A patent/EP3736285A1/en not_active Withdrawn
- 2014-01-16 EA EA201591055A patent/EA201591055A1/ru unknown
- 2014-01-16 KR KR1020217013228A patent/KR20210054026A/ko not_active Withdrawn
- 2014-01-16 MX MX2015009142A patent/MX372787B/es active IP Right Grant
- 2014-01-16 SG SG11201505140XA patent/SG11201505140XA/en unknown
- 2014-01-16 PL PL14702206T patent/PL2945967T3/pl unknown
- 2014-01-16 CA CA2896978A patent/CA2896978A1/en active Pending
- 2014-01-16 KR KR1020157022078A patent/KR102249454B1/ko not_active Expired - Fee Related
- 2014-01-16 HU HUE14702206A patent/HUE049556T2/hu unknown
- 2014-01-16 US US14/759,535 patent/US10724014B2/en not_active Expired - Fee Related
- 2014-01-16 ES ES14702206T patent/ES2796743T3/es active Active
- 2014-01-16 CN CN201480005077.6A patent/CN105121464B/zh not_active Expired - Fee Related
- 2014-01-16 PE PE2015001353A patent/PE20151664A1/es not_active Application Discontinuation
- 2014-01-16 DK DK14702206.5T patent/DK2945967T3/da active
- 2014-01-16 EP EP14702206.5A patent/EP2945967B1/en active Active
- 2014-01-16 SI SI201431607T patent/SI2945967T1/sl unknown
-
2015
- 2015-07-06 IL IL239810A patent/IL239810A0/en unknown
- 2015-07-15 MX MX2019013857A patent/MX2019013857A/es unknown
- 2015-07-16 IL IL239996A patent/IL239996A0/en unknown
-
2019
- 2019-02-08 JP JP2019021752A patent/JP6995069B2/ja not_active Expired - Fee Related
- 2019-08-05 US US16/532,184 patent/US20200199545A1/en not_active Abandoned
-
2020
- 2020-03-13 US US16/818,954 patent/US11702642B2/en active Active
- 2020-06-19 US US16/906,046 patent/US11814654B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506912A5 (enExample) | ||
| JP6345216B2 (ja) | オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途 | |
| KR102092206B1 (ko) | 장기-작용성 glp-1/글루카곤 수용체 작용제 | |
| JP2011526886A5 (enExample) | ||
| JP2016506914A5 (enExample) | ||
| JP2019108394A (ja) | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 | |
| US20150072924A1 (en) | Long-acting oxyntomodulin variants and methods of producing same | |
| HRP20221021T1 (hr) | T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02 | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP6294868B2 (ja) | 液体水性組成物 | |
| JP2014521684A5 (enExample) | ||
| TW201444866A (zh) | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 | |
| JP2011524420A5 (enExample) | ||
| JP2013518115A5 (enExample) | ||
| WO2014074532A2 (en) | Compositions and methods for modulating cell signaling | |
| RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
| JP2016518351A5 (enExample) | ||
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| NO326298B1 (no) | Anvendelse av R'-Glu-Trp-R'' dipeptider i fremstilling av medikamenter | |
| WO2012012600A3 (en) | Peptide compounds for regulating the complement system | |
| JP2013518090A5 (enExample) | ||
| JP2017532965A (ja) | 抗血管新生活性を有するシンデカン−２のフラグメント | |
| CN109328069A (zh) | Il-22在治疗坏死性小肠结肠炎中的用途 | |
| US20220287347A1 (en) | Peptides for treating muscle atrophy | |
| CA2716565C (en) | Pharmaceutical composition for transnasal administration |